The Nanotechnology Characterization Laboratory (NCL) has made significant strides in advancing cancer nanotechnology over the past two decades. Established by the National Cancer Institute in 2004 in collaboration with the US Food and Drug Administration and the National Institute of Standards and Technology, NCL has played a crucial role in bridging the gap between nanotechnology innovations and their clinical applications in oncology.

To celebrate two successful decades of NCL’s contributions to advancing the field of cancer nanotechnology, this symposium brings together NCL scientists, collaborators, and researchers applying nanotechnology to improve current treatment strategies and develop innovative therapies, vaccines, and diagnostics to combat cancer and the detrimental side-effects of many existing standard of care treatments.

The agenda includes presentations across industries, with collaborators from academia, government, and pharma.